#USA #San Diego #oncology research #Tumoroids #Discovery Life Sciences

Discovery Life Sciences Set to Revolutionize Oncology Research with Tumoroids

HUNTSVILLE, Ala. - February 25, 2025 - Discovery Life Sciences, a leading provider of biospecimen solutions and specialty lab services, has announced its participation in the Precision Med Tri-Con taking place from March 11 to March 13, 2025, in San Diego, California. At this significant conference, Discovery will introduce its latest innovation, Tumoroid cell lines, derived from the OncoPro™ Medium by Thermo Fisher Scientific. This new product promises to transform oncology research by providing an advanced predictive tool for drug development and diagnostics.

Innovation in Oncology

According to McLean Collins, President of Biospecimens Products and Services at Discovery, the Tumoroid cell lines are a game-changer in cancer research. These highly predictive models are derived from patient tumors and cultivated as self-organizing multicellular 3D structures. This approach enhances biological relevance compared to traditional 2D cancer models, helping researchers overcome significant challenges in the field.

The Tumoroids are designed to accelerate the identification of life-changing therapies, enabling rapid progress in oncology research. They will complement Discovery's existing offerings in cell-based functional assays and the innovative 10X single-cell portfolio, all aimed at advancing the science of precision medicine.

Key Highlights at Precision Med Tri-Con

At the Tri-Con, Discovery will not only showcase the Tumoroids but also engage in several scientific discussions and presentations:

• - Lunch Talk by Dr. Shawn Fahl: On March 11, Dr. Fahl will lead a presentation titled "From Biorepository to Breakthroughs," focusing on how spatial and transcriptomic analyses can accelerate drug development.
• - Keynote Discussion: On March 12, Dr. Fahl will discuss the latest technical trends in precision medicine in a keynote panel.
• - Poster Presentation: Discovery will also present a poster titled “Cell-Free DNA and Beyond,” offering a comprehensive evaluation of workflows in liquid biopsy within a globally recognized clinical biorepository.

Dr. Fahl expressed enthusiasm about the upcoming event, stating, "This year we will present several exciting studies that underscore our commitment to promoting precision medicine through the integration of advanced technologies and high-quality biospecimens into our workflows. We look forward to engaging with the scientific community and exploring new ways to shape the future of oncology research together."

Commitment to Advanced Technologies

Discovery's investments in cutting-edge technologies, including AI-driven pathology and retrospective clinical biomarker testing workflows, facilitate the extraction of actionable insights from biospecimens. This commitment to innovation aims to deliver significant value to researchers and further the understanding of cancer treatment.

For more details about Discovery Life Sciences and its product offerings, interested parties can visit www.dls.com.

About Discovery Life Sciences

Discovery Life Sciences is a premier provider of biospecimen solutions and specialty lab services that enable the discovery and development of therapeutics and diagnostics aimed at improving patient outcomes. With a vast portfolio of biospecimens, cellular starting materials, and preclinical ADME-Tox solutions, Discovery accelerates research with reliable, high-quality products and expertise. Their comprehensive range of specialized lab services covers genomics, proteomics, cell biology, and molecular pathology, providing essential data for biomarker discovery and clinical studies. Discovery Life Sciences aims to be the most trusted partner in life sciences research and clinical development, dedicated to advancing the biosciences and changing lives.